Thoughts on DESTINY-Breast04 for HER2-low metastatic breast cancer.
Joseph GLIGOROV
Oncologist, Paris, France
Oncologist, Paris, France
New User? Click here to register
Text generated by AI based on an exclusive interview, revised and reviewed by
Benjamin SARFATI
Yazid BELKACEMI
Chairman of the Radiation Oncology Department and the Henri-Mondor Breast Center, Henri- Mondor University Hospital, Créteil, France
Copyright © 2026 - BCU